The European Medicines Agency wants to hear opinions on its proposed policy on sharing and publishing information from clinical trials. The Agency has committed to proactively publish information from clinical trials submitted in support of a marketing authorisation application, once the decision-making process has ended, and sets out a model for sharing commercially confidential information and personal data about patients.
It’s important that the EMA hears from lots of different voices in support of their good proposals. The deadline to respond to this public consultation is 30 September 2013. Read the EMA’s policy paper and how to respond to it here.
Here is our response to the draft proposals.
Joint response from Association Internationale de la Mutualité (AIM), Health Action International (HAI) Europe, International Society of Drug Bulletins (ISDB), and Medicines in Europe Forum (MiEF)